國家衛生研究院 NHRI:Item 3990099045/15380
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906767      Online Users : 928
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15380


    Title: Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer's Disease
    Authors: Lin, YW;Fang, CH;Liang, YJ;Yang, CY;Kuo, WT;Lin, FH
    Contributors: Institute of Biomedical Engineering and Nanomedicine
    Abstract: BackgroundAlzheimer's disease is a neurodegenerative disorder, and A beta aggregation is considered to be the central process implicated in its pathogenesis. Current treatments are faced by challenges such as serious side effects and reduced drug bioavailability. In this study, we developed a drug delivery system for intramuscular injection that uses cellular activity to achieve constant and long-term drug release.MethodsSynthesized mesoporous hydroxyapatite (SHAP) was prepared via co-precipitation, and hydrophobic surface modification using stearic acid was then used to load clenbuterol by physical absorption, thus creating the drug delivery system. Clenbuterol release was achieved through cellular activity, with macrophage uptake triggering lysosome/endosome disruption, cytoplasmic release, extracellular exocytosis, and subsequent systemic circulation.ResultsWe found that clenbuterol-loaded SHAP enabled sustained release for more than 2 weeks and effectively modulated inflammation, reduced A beta oligomer-induced toxicity, and prevented A beta aggregation.ConclusionsOur findings suggest that treatment with clenbuterol loaded in this SHAP delivery system could be a promising strategy for treating Alzheimer's disease.
    Date: 2023-10-05
    Relation: Biomaterials Research. 2023 Oct 05;27:Article number 98.
    Link to: http://dx.doi.org/10.1186/s40824-023-00432-4
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1226-4601&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001081727700001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85173777902
    Appears in Collections:[Feng-Huei Lin] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI001081727700001.pdf4680KbAdobe PDF82View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback